RespireRx Pharmaceuticals Inc (RSPI)

[laker9029]

<I wouldn't be surprised to hear of an announcement of partnership to coincide with the CEO switch.>

I don't know about it coinciding with the management change, that is possible, but in any case, it is pretty obvious Cortex does not have the ability, either talent-wise or financially to commercialize these molecules -- and there is still lots of clinical work to do as well. I wonder if Stoll's remarks about moving ahead with CX717 were part of a strategy to get offer a partner a near-term opportunity, to move ampakines into the commercial use, with CX742 as the real strategic product. That would hopefuly increase the value and reduce the development risk as well IMO. It was noteworthy, I think that a slide showing CX742 was successful in the rat model was inserted kind as a conclusion to the presentation on the trial and prior to answering the question on partnering.

L